528 reports of this reaction
2.6% of all ASENAPINE MALEATE reports
#6 most reported adverse reaction
DYSKINESIA is the #6 most commonly reported adverse reaction for ASENAPINE MALEATE, manufactured by Allergan, Inc.. There are 528 FDA adverse event reports linking ASENAPINE MALEATE to DYSKINESIA. This represents approximately 2.6% of all 20,068 adverse event reports for this drug.
Patients taking ASENAPINE MALEATE who experience dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSKINESIA is a less commonly reported adverse event for ASENAPINE MALEATE, but still significant enough to appear in the safety profile.
In addition to dyskinesia, the following adverse reactions have been reported for ASENAPINE MALEATE:
The following drugs have also been linked to dyskinesia in FDA adverse event reports:
DYSKINESIA has been reported as an adverse event in 528 FDA reports for ASENAPINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSKINESIA accounts for approximately 2.6% of all adverse event reports for ASENAPINE MALEATE, making it a notable side effect.
If you experience dyskinesia while taking ASENAPINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.